Castellano | Euskara | Français | English
DAR No 7: Dabigatran (Pradaxa®) in stroke prophylaxis in patients with atrial fibrillation
Share it
An option for anticoagulation when warfarin or acenocumarol fail
- Dabigatran is an oral anticoagulant that does not require monitoring of prothrombin time (INR).
- In one open trial comparing warfarin, dabigatrin 150 mg/12h showed a lower incidence of stroke or embolic events, and a similar incidence of severe bleeding. Dabigatran 110 mg/12h showed a lower incidence of severe bleeding and no differencein the incidence of stroke or embolic events.
- In centres with adequate INR control there were no differences on the incidence of stroke, embolic events or severe bleeding vs warfarin.
- After commercialization there have been various alerts on the risk of bleeding and there are data on the possible increase in the incidence of myocardial infarctions.
- There are no available headto- head comparisons with other new oral anticoagulants.
